| GNCA Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the GNCA shares outstanding history going back to 2/5/2014:
Also see: GNCA Market Cap History GNCA YTD Return |
GNCA Shares Outstanding History — Genocea Biosciences Share Count Over Time
As of 4/29/2022 Genocea Biosciences has 58.78 million GNCA shares outstanding. Investors often track the GNCA shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows GNCA share count trends over time, with 38 historical shares outstanding datapoints presented, dating back to 2/5/2014.
| GNCA Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GNCA Historical Shares Outstanding: +49.46% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| GNCA Stock Price Chart |
| About Genocea Biosciences Inc |
| Genocea Biosciences is a biopharmaceutical company that discovers and develops cancer immunotherapies using its ATLAS™ platform. The ATLAS platform profiles each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Co.'s GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral cells (NPTs). The GEN-011 NPTs are specific for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived, tumor-specific T cell therapy. Co.'s GEN-009 program is a neoantigen vaccine delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. We show 38 historical shares outstanding datapoints in our coverage of GNCA's shares outstanding history. Understanding the changing numbers of GNCA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like GNCA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching GNCA by allowing them to research GNCA shares outstanding history as well as any other stock in our coverage universe. |
| GNCA Current Stock Quote |
Quotes delayed 20 minutes  Free GNCA Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| GNCA Share Performance |
| Shares Outstanding Peers |
| Genocea Biosciences (GNCA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
GNLX Shares Outstanding History GNMK Shares Outstanding History GNMX Shares Outstanding History GNPX Shares Outstanding History GOSS Shares Outstanding History GOVX Shares Outstanding History GRAY Shares Outstanding History GRCE Shares Outstanding History GRDN Shares Outstanding History GRDX Shares Outstanding History More Healthcare companies » |
GNCA Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
